CEO David Regan discusses Sona’s recently announced study with principal investigator Dr. Carman Giacomantonio MD, MSc., FRCSC on September 20th. The study assesses Sona’s developing ‘THT’ cancer therapy for efficacy and its ability to act as a catalyst to generate immune responses.
In this session, Dr. Carman details the research initiative that is to be undertaken with The Giacomantonio Immuno-Oncology Research Group.